SENTI BIOSCIENCES INC (SNTI) Stock News

USA - Nasdaq - NASDAQ:SNTI - US81726A2096 - Common Stock

2.13 USD

+0.07 (+3.4%)

Last: 12/2/2025, 2:24:20 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SNTI Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Chartmill

News Image

Senti Biosciences Inc (NASDAQ:SNTI) Q3 2025 Earnings Miss Estimates, Stock Falls on Revenue and EPS Shortfall

19 days ago - By: Senti Biosciences, Inc.

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

a month ago - By: Senti Biosciences, Inc.

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

a month ago - By: Benzinga - Mentions: AZTR ADAP CODX KZIA ...

12 Health Care Stocks Moving In Monday's After-Market Session

2 months ago - By: Senti Biosciences, Inc.

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

2 months ago - By: Benzinga - Mentions: BCRX XNCR ADAP SSKN ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 months ago - By: Senti Biosciences, Inc.

Senti Bio to Present at BioJapan

3 months ago - By: Senti Biosciences, Inc.

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

3 months ago - By: Senti Biosciences, Inc.

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Senti Biosciences, Inc.

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

4 months ago - By: Senti Biosciences, Inc.

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

4 months ago - By: Senti Biosciences, Inc.

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

4 months ago - By: Senti Biosciences, Inc.

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

4 months ago - By: Senti Biosciences, Inc.

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

4 months ago - By: ACCESS Newswire - Mentions: AKTX AMIX CNSP NVNO ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

4 months ago - By: Senti Biosciences, Inc.

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

5 months ago - By: Senti Biosciences, Inc.

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

5 months ago - By: Senti Biosciences, Inc.

Senti Bio Participates in Nasdaq Amplify Spotlight Series

5 months ago - By: Senti Biosciences, Inc.

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

6 months ago - By: Senti Biosciences, Inc.

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

6 months ago - By: Senti Biosciences, Inc.

Senti Biosciences Announces New Employment Inducement Grants

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

6 months ago - By: Senti Biosciences, Inc.

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

6 months ago - By: Senti Biosciences, Inc.

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

6 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

6 months ago - By: Senti Biosciences, Inc.

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

7 months ago - By: The Schall Law Firm

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

7 months ago - By: Senti Biosciences, Inc.

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202